Xencor Stock Jumps After Encouraging Phase 1 Results for XmAb819 in Advanced Kidney Cancer
Xencor selected a Phase 3 dose for XmAb819 after early data showed strong responses in heavily pretreated advanced clear cell kidney cancer patients.
/ 1 item
#XNCR↓